HOME >> MEDICINE >> NEWS
Calcium boost to youths' bones could reduce osteoporosis risk

COLUMBUS, Ohio New research on calcium and bone development suggests that efforts to prevent osteoporosis, generally considered a geriatric disease among women, could actually start before puberty.

In the study at The Ohio State University Medical Center, which is the first clinical trial to track calcium's effects on bone density in girls age 8-13 for as long as seven years, researchers found that calcium supplementation significantly increased bone mass development during a critical childhood growth spurt.

The findings suggest that elevated calcium use by pre-adolescent girls is likely to help prevent fractures and osteoporosis much later in life, said Velimir Matkovic, lead author of the study and director of the Osteoporosis Prevention and Treatment Center and the Bone and Mineral Metabolism Laboratory at OSU Medical Center.

The research is published in the January issue of the American Journal of Clinical Nutrition and the Journal of Nutrition.

"Because most bone mass is accumulated during this phase of growth, pre-adolescence may represent the time of highest need for calcium in a female's lifetime," said Matkovic, also a professor of physical medicine and rehabilitation and nutrition.

Matkovic pioneered research on the concept of calcium's relationship to peak bone mass in the 1970s, when he documented differing fracture rates among populations that consumed contrasting levels of dairy products over their lifetime. His initial study, based in Croatia, is cited in "Bone Health and Osteoporosis," a report of the U.S. Surgeon General associated with the federal declaration that 2002-2011 is the Decade of the Bone and Joint.

"The importance of preventing osteoporosis can't be overstated," Matkovic said. "Prevention of this disease will not only improve the population's quality of life, but will also undoubtedly save on the skyrocketing health care costs associated with treatment."

In patients
'"/>

Contact: Emily Caldwell
caldwell.151@osu.edu
614-293-3737
Ohio State University
25-Jan-2005


Page: 1 2 3

Related medicine news :

1. Calcium and vitamin D most effective for treatment of Crohns-related bone loss
2. Calcium channel blocker reduces adverse cardiovascular events in certain patients
3. Calcium-blocker drug slows artery clogging better than beta blocker
4. Calcium-dependent potassium channels as target to increase drug delivery to brain tumors
5. Calcium channel gene may play a role in severity of neurodegenerative brain disease
6. Calcium intake may be associated with reduced risk of colon cancer
7. This summer, Camp Calcium is where the boys are
8. American Heart Association Comment On New England Journal Of Medicine Report OnCalcium Antagonist Nisoldipine (March 5 issue)
9. Daily supplement may boost birthweight of babies in the developing world
10. $4 million grant boosts University of Michigan campaign for a new childrens hospital
11. UC Irvines undergraduate research programs receive $900,000 funding boost

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Calcium boost youths bones could reduce osteoporosis risk

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: